Financials data is unavailable for this security.
View more
Year on year Star Lake Bioscience Co Inc Zhaoqing Guangdong had relatively flat revenues (17.49bn to 17.37bn), though the company grew net income 11.45% from 608.33m to 677.95m. A reduction in the selling, general and administrative costs as a percentage of sales from 5.23% to 5.17% was a component in the net income growth despite flat revenues.
| Gross margin | 15.39% |
|---|---|
| Net profit margin | 5.47% |
| Operating margin | 6.89% |
| Return on assets | 6.50% |
|---|---|
| Return on equity | 13.07% |
| Return on investment | 10.16% |
More ▼
Cash flow in CNYView more
In 2023, Star Lake Bioscience Co Inc Zhaoqing Guangdong increased its cash reserves by 53.91%, or 464.86m. The company earned 2.03bn from its operations for a Cash Flow Margin of 11.66%. In addition the company used 858.79m on investing activities and also paid 701.71m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 4.49 |
|---|---|
| Tangible book value per share | 4.02 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.19 |
|---|---|
| Quick ratio | 0.6038 |
| Total debt/total equity | 0.6593 |
|---|---|
| Total debt/total capital | 0.393 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items increased 11.44%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.63% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 66.18% |
| EPS growth(5 years) | 44.17 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 101.14 |
More ▼
